Molecular glue discovery: large scale instead of lucky strike

(Press-News.org) Cells constantly monitor and recycle their proteins through a tightly regulated waste-disposal system. Proteins that are no longer needed are tagged and broken down by specialized cellular machinery. Recent advances in drug discovery seek to exploit this system by redirecting it toward disease-relevant targets.

This strategy relies on so-called molecular glues, small molecules that induce interactions between proteins that would not normally bind to each other. If a disease-causing protein can be brought into contact with a cellular degradation enzyme, it is selectively eliminated by the cell itself.

Until now, however, most molecular glues have been discovered by chance, limiting their broader therapeutic application.

Large-scale chemistry meets cell-based screening

The new method developed by the teams of Georg Winter (Scientific Director at the AITHYRA Research Institute for Biomedical Artificial Intelligence and Adjunct Principal Investigator at the CeMM Research Center for Molecular Medicine in Vienna, Austria) and Michael Erb (Associate Professor at the Scripps Research Institute in La Jolla, California, U.S.A.). addresses this limitation. Starting from a small molecule that already binds to a target protein, the researchers generated thousands of chemical variants by systematically attaching different molecular building blocks. Each variant subtly reshapes the surface of the protein, potentially enabling new protein–protein interactions.

Crucially, these compounds were screened directly in living cells, without prior purification, using a sensitive assay that reports whether the target protein is being degraded. This enabled rapid identification of active compounds from a vast chemical space.

“Our approach combines high-throughput chemistry with functional testing in cells,” says Miquel Muñoz i Ordoño, co-first author of the study and PhD Student in Georg Winter’s lab. “This allows us to explore chemical diversity at a scale that was previously impractical, while immediately seeing which compounds have a desired biological effect.”

A selective degrader for a leukemia-associated protein

As a proof of principle, the researchers focused on ENL, a protein that plays a central role in certain forms of acute leukemia. From several thousand tested compounds, the team identified a molecule that efficiently and selectively triggers degradation of ENL in leukemia cells.

Further analyses showed that the compound primarily affects ENL and downstream gene programs controlled by this protein, leading to a strong reduction in the growth of ENL-dependent leukemia cells. They also revealed that the compound acts through a cooperative mechanism characteristic of molecular glues. Rather than binding strongly to all interaction partners, it first binds ENL and then creates a new interaction surface that recruits a cellular ubiquitin ligase, which marks ENL for degradation.

“This cooperative mode of action is what makes molecular glues both powerful and selective,” explains Winter. “The compound only becomes active in the right molecular context, which helps limit unwanted effects.”

Systematic discovery of molecular glues

Beyond the specific example of ENL, the study published in Nature Chemical Biology (DOI 10.1038/s41589-025-02137-2) demonstrates a broadly applicable discovery strategy. By combining high-throughput chemistry with functional screening in cells, the researchers show how the identification of molecular glues can be transformed from a serendipitous process into a systematic workflow.

“Our goal is to make proximity-inducing drugs discoverable in a rational and scalable way,” says Winter. “In the long term, this could open up entirely new therapeutic opportunities for proteins that were previously considered undruggable.”

###

The Study “High-throughput ligand diversification to discover chemical inducers of proximity” was published in Nature Chemical Biology on 16 February 2026. DOI: 10.1038/s41589-025-02137-2

Authors: James B. Shaum, Miquel Muñoz i Ordoño, Erica A. Steen, Daniela V. Wenge, Hakyung Cheong, Jordan Janowski, Moritz Hunkeler, Eric M. Bilotta, Zoe Rutter, Paige A. Barta, Abby M. Thornhill, Natalia Milosevich, Lauren M. Hargis, Timothy R. Bishop, Trever R. Carter, Bryce da Camara, Matthias Hinterndorfer, Lucas Dada, Wen-Ji He, Fabian Offensperger, Hirotake Furihata, Sydney R. Schweber, Charlie Hatton, Yanhe (Crane) Wen, Benjamin F. Cravatt, Keary M. Engle, Katherine A. Donovan, Bruno Melillo, Seiya Kitamura, Alessio Ciulli, Scott A. Armstrong, Eric S. Fischer, Georg E. Winter, Michael A. Erb.

Funding: This study was supported by the Austrian Academy of Sciences, as well as by the European Research Council (ERC), the Austrian Science Fund (FWF), and the Vienna Science and Technology Fund (WWTF). Additional support was provided by the Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN), the Ono Pharma Foundation, the Baxter Foundation, the Boehringer Ingelheim Fonds, the Boehringer Ingelheim Stiftung, the German Research Foundation (DFG), the Japan Society for the Promotion of Science (JSPS), the U.S. National Institutes of Health (NIH), and the U.S. National Science Foundation (NSF).

###

The CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences is an international, independent and interdisciplinary research institution for molecular medicine under the scientific direction of Maria Rescigno and Giulio Superti-Furga. CeMM is oriented towards medical needs and integrates basic research and clinical expertise to develop innovative diagnostic and therapeutic approaches for precision medicine. Research focuses on cancer, inflammation, metabolic and immune disorders, rare diseases and aging. The Institute's research building is located on the campus of the Medical University and the Vienna General Hospital.

www.cemm.at

The AITHYRA Research Institute for Biomedical Artificial Intelligence was founded in September 2024 and will combine the best of academic, corporate, and start-up worlds, and will have a mixture of AI and life science experts. In the ultimate expansion state, AITHYRA is envisioned to have 10-14 junior and senior research groups, as well as many global collaborators, very substantial computational and experimental infrastructure, and a state-of-the-art AI-driven robotic lab. AITHYRA is an institute of the Austrian Academy of Sciences (ÖAW) and was established with generous funding from the non-profit Boehringer Ingelheim Foundation.

www.oeaw.ac.at/aithyra

We use artificial intelligence (AI) tools for proofreading and translation purposes. All AI-generated output is reviewed and edited by humans before publication.

For further information please contact:

Wolfgang Däuble
Media Relations Manager / Science Writer
Phone +43-1/40160-70092
wdaeuble@cemm.at

CeMM
Research Center for Molecular Medicine
of the Austrian Academy of Sciences
Lazarettgasse 14, AKH BT 25.3
1090 Vienna, Austria
www.cemm.at

END